Sera Prognostics logo

Sera PrognosticsNASDAQ: SERA

Profile

Sector:

Healthcare

Country:

United States

IPO:

15 July 2021

Next earnings report:

06 November 2024

Last dividends:

N/A

Next dividends:

N/A
$251.93 M
-33%vs. 3y high
56%vs. sector
-vs. 3y high
-vs. sector
-27%vs. 3y high
78%vs. sector
2.35 K
-57%vs. 3y high
99%vs. sector

Price

after hours | Fri, 01 Nov 2024 21:37:44 GMT
$7.55-$0.14(-1.82%)

Dividend

No data over the past 3 years
$24.00 K$80.00 K
$24.00 K-$8.30 M

Analysts recommendations

Institutional Ownership

SERA Latest News

Sera Prognostics Announces Conference Call and Webcast of Third Quarter Fiscal Year 2024 Financial Results on November 6, 2024
prnewswire.com28 October 2024 Sentiment: POSITIVE

SALT LAKE CITY , Oct. 28, 2024 /PRNewswire/ --  Sera Prognostics  Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report third quarter fiscal year 2024 financial results on Wednesday, November 6, 2024, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m.

Sera Prognostics, Inc. (SERA) Q2 2024 Earnings Call Transcript
seekingalpha.com09 August 2024 Sentiment: NEUTRAL

Sera Prognostics, Inc. (NASDAQ:SERA ) Q2 2024 Earnings Conference Call August 7, 2024 5:00 PM ET Company Participants Peter DeNardo - CapComm Partners Zhenya Lindgardt - President & CEO Austin Aerts - CFO Conference Call Participants Andrew Brackmann - William Blair Dan Brennan - TD Cowen Operator Good afternoon, and welcome to the Sera Prognostics Conference Call to review second quarter fiscal year 2024 results. [Operator Instructions] As a reminder, this call is being recorded for replay purposes.

Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Lags Revenue Estimates
zacks.com07 August 2024 Sentiment: NEGATIVE

Sera Prognostics, Inc. (SERA) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.34 per share a year ago.

SERA PROGNOSTICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS
prnewswire.com07 August 2024 Sentiment: POSITIVE

SALT LAKE CITY , Aug. 7, 2024 /PRNewswire/ -- Sera Prognostics Inc. , The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the second quarter of 2024 ended June 30, 2024. Recent Highlights: Publication of positive AVERT PRETERM TRIAL (Serum Assessment of Preterm Birth Outcomes Compared to Historical Controls) results in international peer-reviewed journal, Diagnostics , with coverage on front page of publication.

Sera Prognostics PreTRM® Test Prevention Strategy Demonstrates 18% Reduction in Severe Neonatal Morbidity and Mortality in Newly Published AVERT Trial
prnewswire.com09 July 2024 Sentiment: POSITIVE

Sera Prognostics Announces Publication of Positive AVERT PRETERM TRIAL Results in the International Peer-Reviewed Journal, Diagnostics SALT LAKE CITY , July 9, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the publication in Diagnostics, an international, peer-reviewed, open access journal on medical diagnosis, of the top-line results from the AVERT PRETERM TRIAL (Serum Assessment of Preterm Birth Outcomes Compared to Historical Controls), conducted at ChristianaCare in Wilmington, Delaware. PreTRM® test-and-treat strategy demonstrates statistically and clinically significant improvement in neonatal health outcomes and hospital length-of-stay Previously, Sera reported that both co-primary outcomes—reduction of severe neonatal morbidity or neonatal death; and decreased length of neonatal hospital stay—met their endpoints, and the improvements in outcome with a PreTRM® test-and-treat approach were statistically significant.

SERA PROGNOSTICS EXPECTED TO BE ADDED TO RUSSELL 2000 AND 3000 INDEXES
prnewswire.com28 May 2024 Sentiment: POSITIVE

SALT LAKE CITY , May 28, 2024 /PRNewswire/ --  Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it has been added to the preliminary list of the Russell Small-Cap 2000 and Russell 3000 indexes as part of the Russell indexes annual reconstitution. "We are pleased to be included in the preliminary list of the Russell 3000 Index, as it marks another step forward for Sera during a year in which we expect to achieve several milestones in advancing our role as 'The pregnancy company' to improve maternal and neonatal healthcare outcomes," said Zhenya Lindgardt, President and CEO of Sera Prognostics.

Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2024 Financial Results on May 8, 2024
PRNewsWire29 April 2024 Sentiment: POSITIVE

SALT LAKE CITY, April 29, 2024 /PRNewswire/ -- Sera Prognostics Inc., known as The Pregnancy Company® (NASDAQ: SERA), which aims to enhance maternal and neonatal health through cutting-edge pregnancy biomarker information for healthcare providers and patients, will release its first quarter fiscal year 2024 financial results on Wednesday, May 8, 2024, after market close. A conference call and live webcast will be held at 5:00 p.m. to review operational achievements, financial outcomes, and important subjects.

Sera Prognostics (SERA) Upgraded to Buy: Here's What You Should Know
Zacks Investment Research25 March 2024 Sentiment: POSITIVE

Sera Prognostics (SERA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Sera Prognostics' PreTRM: A Speculative Buy In Women's Health
Seeking Alpha24 March 2024 Sentiment: POSITIVE

Sera Prognostics specializes in women's health diagnostics with its PreTRM test, offering personalized risk assessment for preterm birth. The PreTRM test analyzes specific proteins and gestational age to provide accurate risk assessment for preterm birth. Sera Prognostics specializes in women's health through its flagship product, PreTRM, with an 88% sensitivity for predicting preterm births.

Sera Prognostics, Inc (SERA) Q4 2023 Earnings Call Transcript
Seeking Alpha20 March 2024 Sentiment: POSITIVE

Sera Prognostics, Inc (SERA) Q4 2023 Earnings Call Transcript

  • 1(current)

What type of business is Sera Prognostics?

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

What sector is Sera Prognostics in?

Sera Prognostics is in the Healthcare sector

What industry is Sera Prognostics in?

Sera Prognostics is in the Medical Devices industry

What country is Sera Prognostics from?

Sera Prognostics is headquartered in United States

When did Sera Prognostics go public?

Sera Prognostics initial public offering (IPO) was on 15 July 2021

What is Sera Prognostics website?

https://seraprognostics.com

Is Sera Prognostics in the S&P 500?

No, Sera Prognostics is not included in the S&P 500 index

Is Sera Prognostics in the NASDAQ 100?

No, Sera Prognostics is not included in the NASDAQ 100 index

Is Sera Prognostics in the Dow Jones?

No, Sera Prognostics is not included in the Dow Jones index

When was Sera Prognostics the previous earnings report?

No data

When does Sera Prognostics earnings report?

The next expected earnings date for Sera Prognostics is 06 November 2024